The FDA has approved Sanofi’s Soliqua 100/33, or insulin glargine and lixisenatide injection, as a treatment for type 2 diabetes in adults whose disease is not adequately managed on basal insulin or lixisenatide. The drug will be available as a single prefilled pen in January.